Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)

This study has been completed.
Information provided by (Responsible Party):
Targacept Inc. Identifier:
First received: June 14, 2010
Last updated: November 27, 2013
Last verified: November 2013

Study is to assess the effectiveness of TC-6499 in the treatment of constipation predominant IBS patients over a 28-day period.

Condition Intervention Phase
Irritable Bowel Syndrome
Drug: TC-6499
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof-of-Principle Study to Evaluate the Safety, Tolerability, and Efficacy of TC-6499-12 in the Treatment of Constipation Predominant IBS

Resource links provided by NLM:

Further study details as provided by Targacept Inc.:

Primary Outcome Measures:
  • Change from baseline in global IBS symptom relief score [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Primary efficacy endpoint assessed weekly using patient's response to a global symptom relief question rating their relief of IBS symptoms over the past week compared to before study entry.

Secondary Outcome Measures:
  • Weekly number of spontaneous bowel movements (SBM) [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    The number of spontaneous bowel movements not associated with rescue medication will be assessed through patient self-reports

  • Severity of pain, bloating, degree of straining, and stool consistency [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Severity of pain, bloating, degree of straining, and stool consistency will be assessed through daily patient self-reports

Enrollment: 24
Study Start Date: May 2010
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TC-6499 Drug: TC-6499
5mg enteric-coated oral hard gelatin capsule, administered twice daily
Placebo Comparator: Placebo Drug: Placebo
placebo as enteric-coated oral hard gelatin capsule, administered twice daily

Detailed Description:

This is a randomized, double blind, placebo controlled study of a maximum of 24 subjects with constipation predominant irritable bowel syndrome (IBS-C). Sixteen subjects will receive active treatment and 8 subjects will receive matching placebo. There will be a 21-day screening phase before 1st study drug administration on Day 1.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Men with IBS-C (ROME III) between 18 and 65 years of age, inclusive.
  • Women with IBS-C (ROME III) between 55 and 65 years of age, or 18 to 55 years of age with documentation of non-childbearing potential status (surgical sterilization or one year post last menses with elevated FSH/LV).
  • All subjects should have a body mass index (BMI) between 18 and 34 kg/m2, inclusive and a body weight of not less than 45 kg.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01149200

United Kingdom
Quotient Clinical Ltd
Edinburgh, United Kingdom
Quotient Clinical Ltd
Ruddington, United Kingdom
Sponsors and Collaborators
Targacept Inc.
Principal Investigator: Stuart Mair, MB, ChB Quotient Bioresearch Ltd
  More Information

No publications provided

Responsible Party: Targacept Inc. Identifier: NCT01149200     History of Changes
Other Study ID Numbers: TC-6499-12-CLP-004
Study First Received: June 14, 2010
Last Updated: November 27, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Targacept Inc.:
Irritable Bowel Syndrome

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Colonic Diseases
Colonic Diseases, Functional
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Pathologic Processes
Signs and Symptoms
Signs and Symptoms, Digestive processed this record on November 24, 2014